- Home
- QSI vs FHTX Comparison
QSI vs FHTX Comparison
Compare QSI & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QSI | FHTX |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.7M | 247.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | QSI | FHTX |
|---|---|---|
| Price | $1.26 | $5.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $2.88 | ★ $11.43 |
| AVG Volume (30 Days) | ★ 4.2M | 166.5K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,177,000.00 | ★ $24,518,000.00 |
| Revenue This Year | N/A | $47.50 |
| Revenue Next Year | $159.68 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 40.20 | N/A |
| 52 Week Low | $0.95 | $2.95 |
| 52 Week High | $5.77 | $6.79 |
Technical Indicators
Market Signals| Indicator | QSI | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.37 | 68.55 |
| Support Level | $1.18 | $4.21 |
| Resistance Level | $1.31 | $4.59 |
| Average True Range (ATR) | 0.10 | 0.29 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 20.83 | 85.07 |
Price Performance
Historical ComparisonAbout QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.